Table 2 Demographics and baseline characteristics of study population

From: Discriminating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and comorbid conditions using metabolomics in UK Biobank

 

ME/CFS

Hypertension

Depression

Asthma

IBS

Hay fever

Hypothyroidism

Migraine

C2

Sample size

1194

13559

 

2522

 

6406

 

859

 

3025

 

2258

 

1551

 

53009

 

Female, %

73.9

47.5

****

66.6

***

54.1

****

67.4

*

45.9

****

86.7

****

77.4

0.034

53.5

****

Age at recruitment, median

56

59

****

52

****

52

****

53

****

51

****

57

0.007

52

****

53

****

Hand grip strength (kg), median

25

31

****

28

****

31

****

28

****

33

****

26

0.01

27

****

30

****

Pulse rate, median

71.8

69.5

****

68

****

68

****

68

****

67.5

****

67.5

****

67.5

****

67.5

****

Body mass index, median

26.6

27.8

****

25.9

*

26.1

*

25.2

****

25.6

****

26.2

0.04

25.2

****

25.8

0.201

Basal metabolic rate (kj), median

5845

6749

****

6000

**

6330

****

5774

0.659

6665

****

5674

****

5701

*

6293

****

Tiredness/lethargy, %

89.3

43.9

****

70.2

****

49.3

****

59.3

****

45.6

****

53.1

****

53.3

****

43

****

Depressed mood, %

39.4

17.4

****

53.7

****

21

****

26.4

****

16.7

****

20.6

****

23.4

****

17.9

****

Sleeplessness/insomnia, %

85.5

74.9

****

82

0.009

72.4

****

78

**

68.5

****

77.5

****

75.2

****

69.1

****

Mood swings, %

55.7

39.3

****

78.3

****

41.9

****

52.2

0.189

38.1

****

43

****

48

**

39

****

Prev. Stressful event(s), %

59

40.4

****

53.1

*

44

****

45.8

****

39.9

****

43.5

****

43.3

****

39.3

****

Pain, %

80.7

52.9

****

61.3

****

55.9

****

67.6

****

51.2

****

54.4

****

83.5

0.068

49.7

****

IPAQ activity group

  

****

 

****

 

****

 

****

 

****

 

****

 

****

 

****

 Low

21.6

33.1

 

31.8

 

36.6

 

33.6

 

33.6

 

33.9

 

30.4

 

36.9

 

 Moderate

24.7

14.2

 

17.4

 

14.4

 

12.7

 

15.9

 

13.3

 

17

 

13.1

 

 High

32.7

33.2

 

33.5

 

32.3

 

34.9

 

35.9

 

32.8

 

35.2

 

32.6

 

Cholesterol-lowering medication, %

15.7

9.7

****

0.7

****

0.9

****

0.5

****

0.6

****

1.7

****

0.6

****

0.8

0.06

Fish oil supplements, %

41.3

31.8

****

27.2

****

26.9

****

29.9

****

27.7

****

34.1

**

27

****

27.9

****

  1. Mann-Whitney U test and Chi-square test of independence with Yates continuity correction were performed on numerical and categorical data respectively comparing ME/CFS against comorbid and C2 cohorts. Significance is denoted as *P < 0.0056 (Bonferroni cutoff accounting for 9 cohorts tested against ME/CFS including C1, see Supplementary Data 3), **P < 0.0001, ***P < 0.00001, ****P < 0.000001. Missing values are not shown in this table. ‘Overall pain’ is a surrogate variable summarising all reported pain types; additional details and data fields and missing values are available in Supplementary Data 3.
Back to article page